All azoospermic males should be screened for cystic fibrosis mutations before intracytoplasmic sperm injection.
We assessed the frequency of CFTR mutations in groups with varying degrees of sub-fertility and compared these groups to a fertile male group with proven paternity. Screening for CFTR mutations should be routine for all azoospermic males, irrespective of obstructive or non-obstructive etiology, prior to proposing ICSI treatment. CFTR testing has no value in the investigation of non-azoospermic infertile males.
Mocanu
Edgar
E
Human Assisted Reproduction Ireland, Rotunda Hospital, and Royal College of Surgeons in Ireland, Dublin, Ireland. emocanu@rcsi.ie
Shattock
Richard
R
Barton
David
D
Rogers
Melissa
M
Conroy
Ronan
R
Sheils
Orla
O
Collins
Claire
C
Martin
Cara
C
Harrison
Robert
R
O'Leary
John
J
D053713:Azoospermia / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D016022:Case-Control Studies; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000235:genetics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D004252:DNA Mutational Analysis; D005787:Gene Frequency; D006580:Genetic Carrier Screening; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D007248:Infertility, Male / Q000209:etiology / Q000235:genetics / Q000628:therapy; D008297:Male; D009154:Mutation; D011237:Predictive Value of Tests; D011379:Prognosis; D020554:Sperm Injections, Intracytoplasmic
D019005:Cystic Fibrosis Transmembrane Conductance Regulator